RT info:eu-repo/semantics/article
T1 Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain
A1 Bravo, Lidia
A1 LLorca-Torralba, Meritxell
A1 Berrocoso, Esther
A1 Micó, Juan Antonio
A2 Neurociencias
A2 Psicología
K1 chronic pain
K1 neuropathic pain
K1 monoamines
K1 antidepressants
K1 noradrenaline
K1 serotonin
AB Monoamines are involved in regulating the endogenous pain system and indeed,peripheral and central monoaminergic dysfunction has been demonstrated in certaintypes of pain, particularly in neuropathic pain. Accordingly, drugs that modulate themonaminergic system and that were originally designed to treat depression are nowconsidered to be first line treatments for certain types of neuropathic pain (e.g., serotoninand noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced bythese drugs seems to be mediated by inhibiting the reuptake of these monoamines,thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particularinterest to study the monoaminergic mechanisms involved in the development andmaintenance of chronic pain. Other analgesic drugs may also be used in combinationwith monoamines to facilitate descending pain inhibition (e.g., gabapentinoids andopioids) and such combinations are often also used to alleviate certain types ofchronic pain. By contrast, while NSAIDs are thought to influence the monoaminergicsystem, they just produce consistent analgesia in inflammatory pain. Thus, in thisreview we will provide preclinical and clinical evidence of the role of monoamines inthe modulation of chronic pain, reviewing how this system is implicated in the analgesicmechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs andhistaminergic drugs
PB FRONTIERS MEDIA SA
SN 1662-453X
YR 2019
FD 2019-11
LK http://hdl.handle.net/10498/22180
UL http://hdl.handle.net/10498/22180
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 04-mar-2021